menu

Loading...

Should I Buy VYNE? VYNE 2026 Analysis - Intellectia AI™

Should You Buy Vyne Therapeutics Inc (VYNE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.600

1 Day change

0.83%

52 Week Range

2.600

Analysis Updated At

2026/02/27

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Vyne Therapeutics Inc (VYNE) is not a strong buy at the moment for a beginner, long-term investor. The stock lacks clear positive catalysts, has weak financial performance, and shows no significant trading trends or technical signals to suggest an immediate buying opportunity.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 59.964, and moving averages are converging, suggesting no clear trend. The pre-market price is down 5.83%, trading near the S1 support level of 0.561.

Positive Catalysts

Revenue increased by 39.67% YoY in Q3 2025, and gross margin remains strong at 100%.

Neutral/Negative Catalysts

Net income dropped significantly (-40.12% YoY), EPS declined (-41.38% YoY), and there is no recent news or significant trading activity from insiders, hedge funds, or Congress.

Financial Performance

In Q3 2025, revenue increased to $169,000 (+39.67% YoY), but net income dropped to -$7,280,000 (-40.12% YoY) and EPS fell to -0.17 (-41.38% YoY). Gross margin remained flat at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

2 Analyst Rating

Wall Street analysts forecast VYNE stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.600

Low

2

Averages

2

High

2

Current: 0.600

Low

2

Averages

2

High

2

H.C. Wainwright

Joseph Pantginis

Buy

to

Neutral

downgrade

AI Analysis

2025-07-30

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

AI Analysis

2025-07-30

downgrade

Buy

to

Neutral

Reason

H.C. Wainwright analyst Joseph Pantginis downgraded VYNE Therapeutics to Neutral from Buy.

H.C. Wainwright

H.C. Wainwright

Buy

to

Neutral

downgrade

$4.50

2025-07-30

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$4.50

2025-07-30

downgrade

Buy

to

Neutral

Reason

H.C. Wainwright downgraded VYNE Therapeutics to Neutral from Buy and removed the firm's prior $4.50 price target after the company's Phase 2b trial assessing repibresib in nonsegmental vitiligo did not achieve its primary endpoint and also missed the secondary endpoint. The Phase 2b result is "a surprise to us" that "puts the company in a precarious position," the analyst tells investors. While stating that the company ends this trial in "a relatively stable financial position," the firm says the current risk profile "pushes us to the sidelines," pending visibility on the path forward for repibresib, additional VYN202 data and/or the acquisition of new assets to pursue.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VYNE

Unlock Now

People Also Watch